{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Dyne Therapeutics, Inc. technically bullish or bearish?
As of April 23, 2025, the market trend is mildly bearish, influenced by daily moving averages and weekly Bollinger Bands indicating bearish momentum, despite some counterbalance from a mildly bullish MACD.
Who are in the management team of Dyne Therapeutics, Inc.?
As of March 2022, the management team of Dyne Therapeutics, Inc. includes Mr. Jason Rhodes as Executive Chairman and Mr. Joshua Brumm as President, CEO, and Director.
What does Dyne Therapeutics, Inc. do?
Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for genetically driven diseases, with a market cap of approximately $1.24 billion and a recent net profit of -$115 million. The company is classified as small-cap and operates in the Pharmaceuticals & Biotechnology industry.
How big is Dyne Therapeutics, Inc.?
As of Jun 18, Dyne Therapeutics, Inc. has a market capitalization of $1.24 billion, with net sales of $0.00 million and a net profit of -$367.12 million over the latest four quarters. The company reported shareholder's funds of $629.84 million and total assets of $691.23 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
